Agile Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative women’s healthcare products that address unmet needs.   Agile was founded in 1997 and is headquartered in Princeton, New Jersey.

Agile’s lead product is AG200-15; a low dose, weekly contraceptive patch that is ready to begin Phase 3 clinical development.

The product will compete in the $3+ billion short-term, hormonal contraceptive market (consisting of oral contraceptives, patch, ring and injectables). It capitalizes on a strong consumer need for more convenient contraceptive options (i.e. not needing to take a pill every day). Ortho Evra® validated the large market opportunity achieving in excess of $400 million in sales before it suffered significant losses due to revised FDA labeling from safety concerns.

Agile’s unique patented technology provides a product profile designed to maximize patient comfort and appeal while also providing safe and effective contraception.

Agile also signed a Clinical trial agreement with NIH for developing a progestin-only contraceptive patch, AG1000, that also utilizes technology. The product is moving into Phase 2 development. It will offer estrogen free contraception for breast-feeding mothers and other women where the use of estrogen for contraception is not recommended. A weekly patch overcomes the major drawback of progestin only pills, where timing and consistency of dosing is a concern in terms of efficacy and side effects.